Quantum BioPharma (QNTM) Receives FDA Green Light to Move Lucid-MS Into Phase 2 Testing

The FDA IND approval marks a pivotal step for the company’s lead compound, known as Lucid-MS. What sets Quantum BioPharma’s proprietary treatment apart from most existing MS therapies is its mechanism. Lucid-MS previously completed phase 1 clinical trials, showing a favorable safety profile and being well tolerated. LOS ANGELES, CA - September 25, 2026 ( NEWMEDIAWIRE ) - A green light from the U.S. Food and Drug Administration (“FDA”) can turn years of laboratory work into a real shot at treating patients, and that is exactly what just happened for one biopharmaceutical company. Quantum BioPharma (NASDAQ: QNTM) , a company focused on neurodegenerative and metabolic disorders, announced that the FDA has approved its Investigational New Drug (“IND”) application for Lucid-MS , clearing the path to phase 2 clinical testing of its multiple sclerosis (“MS”) candidate. The announcement marks a pivotal step for the company’s lead compound, known as Lucid-MS. With the IND now approved, Quantum BioPharma can begin recruiting patients and administering the drug in a controlled clinical setting, something that… Read More Please see full terms of use and disclaimers on the InvestorBrandNetwork